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Abstract
Backround: Multiple sclerosis is a neurodegenerative disorder with a wide range in disease course
severity. Many factors seem to be implicated in multiple sclerosis disease course, and diet has been
suggested to play a role. Because limited data is present in the literature it was investigated whether
variations in dietary intake may be related to the severity of the disease course in multiple sclerosis.
Methods: Using a food diary during 14 days, the dietary intake of 23 nutrients and vitamins was
measured in patients with primary progressive (n = 21), secondary progressive (n = 32), and benign
multiple sclerosis (n = 27) and compared to each other. The intake measured was also compared
to the intake of the Dutch population and to the recommended daily allowance.
Results: Compared to the other MS groups, the secondary progressive MS patients had a lower
intake of magnesium, calcium and iron. The total group of MS patients had, compared to the Dutch
population, a lower intake of folate, magnesium and copper and a lower energy intake. Compared
to the daily recommended allowance, the MS patients had a lower than recommended intake of
folic acid, magnesium, zinc and selenium.
Conclusion: Magnesium, calcium and iron intake may possibly be related to MS disease
progression, and should receive further attention. This is important because no effective
neuroprotective treatment for MS patients is available.
Background
Multiple sclerosis (MS) is a common neurodegenerative
autoimmune mediated disorder of the central nervous
system. The typical clinical presentation of MS is that of a
relapsing-remitting disorder. The majority of MS patients
accumulates irreversible physical disability in time and
switch to a secondary progressive form in which there is a
continuous downhill course that may still be accompa-
nied by overlapping relapses. However, a subgroup of
patients with relapsing-remitting MS shows a benign
course with no disease progression and minimal disability
decades after the first manifestations. Eventually, these
patient may switch to a progressive state.
A systematic review of longitudinal studies revealed that
about 25% of patients with MS have a benign disease
course [1]. There is also a primary progressive form of MS
in which patients show progression of disability from the
onset of disease with or without overlapping relapses.
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in disease course. Genetic factors may contribute to the
clinical phenotype, as well as environmental factors. An
important environmental factor is diet. Experimental, epi-
demiological and clinical studies suggest that nutritional
factors may influence the incidence as well as the course
of MS [2].
For MS patients disease modifying drugs, such as beta
interferons, are used in an attempt to modify the disease
course. These medications are prone for side effects, and
should be used cautiously. Patients may also be treated
unnecessary while there is a prospect of a benign course.
If dietary intake can be related to disease course severity, it
might be a way to influence the course of MS as an alter-
native or complementary strategy. However, the relation
between dietary intake and MS disease course is, up to this
date, not clear [2].
Therefore it was decided to investigate whether there are
differences in nutritional intake between patients with dif-
ferent MS disease courses that may play a role in disease
course severity. Also the nutritional intake was compared
to the Dutch population and to the recommended daily




The study was approved by the medical ethics committee
of the University Medical Centre Groningen. All patients
provided written informed consent prior to inclusion in
the study. A total of 80 patients with MS were enrolled: 27
with a benign course, 32 with secondary progressive MS,
and 21 with primary progressive MS. Benign course in MS
was defined as an Expanded Disability Status Scale
(EDSS) score of 3.0 or less, despite at least 10 years of dis-
ease duration, and without disease progression [1].
Dietary assessment
The patients were extensively informed on how to keep a
food diary at home. A food diary was developed in close
collaboration with the dietary counselor of the University
Medical Centre Groningen. Each patient recorded on a
daily basis all items of food and drinks consumed in a log-
book that was presented to them. For each day, the log-
book had the following sections: at breakfast, during the
morning, at lunch, during the afternoon, at dinner, and
during the evening. Per section a list of commonly con-
sumed items was presented that could be marked/num-
bered. For example: the section breakfast had a list
containing '...slices of white bread, ...slices of whole wheat
bread,..biscuits,...crackers', etc. Then the kind of butter
was asked for, then the topping of the bread (what kind
and amount of meat, what kind and amount of cheese,
and so on).
For accuracy, the dietary assessment took place over a
period of 14 consecutive days, and outside holidays or
other festivities such as Easter or Christmas. Patients were
asked to provide all possible information about prepara-
tion, i.e, one egg for breakfast, boiled or baked. Also the
use of food supplements was scored. The presence of co-
morbidity was scored as well (i.e. hypertension). The
information in the log-books were then entered in a data-
base. Computerized analyses were subsequently per-
formed using a dietary software program based on the
validated and widely used Dutch nutrient database [3]
which covers detailed information on energy and nutri-
ents calculated per 100 grams of 1603 food items. Based
on the diary, total daily intake amounts of 23 nutrients
were calculated for all food items consumed. Also, the
body mass index (BMI) was assessed by dividing the body
weight by the square of the body height.
Serum levels
Vitamin A (measured as retinol), vitamin C (measured as
ascorbine-acid), vitamin B1 (measured as thiamindiphos-
phate), vitamin B2 (measured as flavin-adeninedinucle-
otide in EDTA-anti-coagulated whole blood), vitamin B6
(measured as pyridoxal-5'-phosphate in EDTA-anti-coag-
ulated whole blood) were analyzed by HPLC. Serum vita-
min B12 and serum folate were analyzed with an
immunofluorometric method (Autodelfia™, Wallac Oy,
Turku, Finland). Vitamin E was measured as the sum of α-
tocoferol and γ-tocoferol. Magnesium was determined
with the Xylidyl blue method, calcium with the CPC
method and iron with the ferene method (all Ecoline®
MEGA, Holzheim, Germany).
Comparison of food intake to Dutch population/
recommended daily allowance
Dietary values of daily nutritional intake in the Dutch
population were retrieved from the Dutch Organization
for Applied Scientific Research [4]. The values were
obtained from an at random sample of 5.958 individuals
in the Dutch population with an age below 75 years, and
were presented in age subgroups. For an accurate assess-
ment we compared the daily nutritional intake of the
patients from our study group with the corresponding
subgroups.
Statistical Analysis
Differences between the groups were assessed by ANOVA
and Student's t-test (two-tailed); nonparametric tests were
used when variables did not have normal distribution.
Only when results between the three groups were signifi-
cant, further comparisons were done using Dunn's multi-
ple comparisons test. Because of the number of items
measured, the Bonferroni correction was applied to cor-
rect for significant results by coincidence. The results are
presented as means ± SD, or median [range]. Pearson and
Spearman correlation analysis test was performed to studyPage 2 of 6
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two-tailed significance level.
Results
The results are presented in table 1 and Additional file 1.
All patients filled in the food diary with accuracy. There
were no patients with special diets such as vegan, vegetar-
ian or gluten free. There were no differences between the
BMI between the groups (p > 0.05), nor were there differ-
ences in the number of patients with over- or underweight
(p > 0.05, data not shown). The most striking result was
an approximately 20% lower intake of magnesium (p =
0.009) and a 15% lower intake of calcium (p = 0.03) in
patients with secondary progressive MS compared to
patients with either benign or primary progressive MS. Per
group only a few patients used food supplements that
were mostly herbal based. No relation could be found
between the use of supplements and disease course, nor
between the dietary intake and the presence of co-morbid-
ity (data not shown). Serum levels were within normal
range, did not differ between the groups, and did not cor-
relate with intake (data not shown, all p > 0.05). Com-
pared to Dutch population the intake of the following
nutrients was significantly lower in MS patients: protein
(p < 0.002), SAFA (p = 0.002), MUFA (p < 0.002), total fat
(p = 0.005), cholesterol (p = 0.01), folic acid (p < 0.002),
magnesium (p = 0.002) and copper (p = 0.01). Compared
to the daily recommended allowance it was found that the
intake of folic acid, magnesium, zinc, copper and sele-
nium in MS patients is below the daily recommendation
(Additional file 1.). Total energy intake was lower in the
MS group than in the Dutch population (p < 0.05).
Discussion
Patients with secondary progressive MS have a more
severe disease course than patients with a benign course.
The stepwise accumulating disability following exacerba-
tions is believed to be caused by axonal injury in the focal
white matter lesions in the central nervous system
through inflammatory mechanisms [5,6]. A slowly pro-
gressive axonal degeneration may be the mechanism
responsible for the progressive worsening in progressive
multiple sclerosis (both secondary and primary).
Magnesium
Magnesium is neuroprotective in models of white matter
ischemia and traumatic axonal injury [7], and improves
neurological outcome in patients with neural damage due
to lacunar infarctions [8]. The exact mechanism of neuro-
protection by magnesium remains unclear, but may be
relevant for explaining a possible inverse association
between magnesium intake and tissue damage in MS. This
neuroprotective property of magnesium in lesions affect-
ing the white matter of the central nervous system may be
relevant for explaining a possible inverse association
between magnesium intake and tissue damage in MS.
Magnesium regulates more than 300 metabolic processes
[9] yet the exact mechanisms providing axonal protection
remain uncertain. Those that may be implicated in play-
ing a protective role include energy metabolism, mem-
brane stability, protein and DNA synthesis [10], and
inhibition of the inducible enzyme nitric oxide synthase
(iNOS) [11]. The appearance of iNOS in astrocytes and
macrophages in lesions of MS gives rise to the production
of high amounts of nitric oxide (NO) as well as superox-
ide radicals. These radicals can promote oligodendrocyte
injury, demyelination, and axonal damage [12]. Axons
may degenerate because NO can inhibit mitochondrial
respiration, leading to intraaxonal accumulation of Na+
and Ca2+ ions [13]. Inhibition of iNOS by magnesium
would therefore be considered neuroprotective.
Interestingly, a small post mortem study showed that
magnesium concentrations in central nervous tissue and
visceral organs obtained from MS patients were signifi-
cantly lower than seen in controls [14]. The most marked
reduction of Mg content was observed in CNS white mat-
ter including the demyelinated plaques of MS patients.
Whether or not these significantly lower Mg contents
found in CNS and visceral organs of MS patients may play
an essential role in the demyelinating process remain
unclear, but this lower Mg content might have a relation
Table 1: Patient characteristics
Multiple sclerosis Benign* Secondary progressive Primary progressive
Number 27 32 21
Age (years, mean ± SD) 49.7 ± 10.3 50.7 ± 9.9 52.4 ± 8.7
Gender (F/M) 18/9 21/11 14/7
Disease duration (years, mean ± SD) 20.7 ± 8.2 20.2 ± 8.6 12.0 ± 4.8
EDSS score (median, range) 2.0 (0.0 – 3.0) 7.0 (4.5 – 8.5) 6.0 (2.5 – 8.0)
BMI (± SD) 23.8 ± 5.2 25.6 ± 5.8 24.9 ± 5.6
F: female; M: male; SD: standard deviation; EDSS: Expanded Disability Status Scale; BMI: Body Mass Index (kg/l2).
*Defined as an Expanded Disability Status Scale (EDSS) score of 3.0 or less, despite at least 10 years of disease duration. Score 0 = no disability, 10 
= death [1].Page 3 of 6
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We found a lower intake of magnesium in the total MS
group compared to the Dutch population (p = 0.001).
Calcium
On a high calcium diet, vitamin D supplementation pre-
vents experimental autoimmune encephalomyelitis [15],
which serves as an animal model for the inflammatory
component of MS. However, this protective effect was
abolished with a low calcium diet, and restored with a
high calcium diet [16], indicating that the positive effect
of vitamin D can be increased by calcium. Interestingly, a
pilot study in a small group of MS patients found that die-
tary supplement with magnesium, calcium and vitamin D
resulted in a significant decrease in relapse rate [17]. A low
calcium intake may therefore be considered negative to
MS disease course, and may be reflected in our results,
since the primary progressive MS patients have a lower
calcium intake than the patients with a benign disease
course.
Iron
Iron is considered an important factor in the pathogenesis
of multiple sclerosis [18]. Iron may cause neuronal dam-
age by acting as a catalyst for hydroxyl radical formation
[19], leading to lipid peroxidation [20] and stimulating
oxidative damage to proteins [21]. Limitation of iron
intake may provide protection from developing experi-
mental autoimmune encephalomyelitis [22]. The differ-
ence in iron intake between the secondary and primary
progressive patients found in this clinical study suggests
that iron may play a role in MS disease progression.
Folic acid
Compared to the Dutch population, protein, cholesterol
and folic acid intake was significantly lower in the MS
group. Folates and vitamin B12 have fundamental roles in
the central nervous system at all ages, especially the
methionine-synthase mediated conversion of homo-
cysteine to methionine, which is essential for nucleotide
synthesis. Deficiencies in folic acid (as vitamin B6 or vita-
min B12) are associated with elevated plasma levels of
homocysteine. Elevated plasma homocysteine levels in
patients with secondary progressive MS compared to
healthy controls have been found [23], suggesting a pos-
sible link between the vitamin B status and MS progres-
sion. In an earlier study we found higher homocysteine
levels in MS patients as compared to healthy controls, but
this was unrelated to disease progression, or deficiencies
in vitamins B6, B12 or folic acid [24].
Other nutrients
As others [25], we could not find an association between
antioxidant intake (vitamin C, E, and selenium) or serum
levels and MS disease progression.
In lipid research, limitation of saturated fatty acid intake
[26], and supplementation with unsaturated fatty acids in
combination with more vegetables [27] would favour
prognosis in relapsing-remitting MS. This may be related
to anti-inflammatory properties of the omega-3-fatty
acids [28]. We did not find a difference in the fatty acids
intake between the MS groups and no relation to disease
course severity.
Serum levels
We found no difference in the serum levels of the vitamins
or trace elements between the MS groups. This may raise
the question if the found differences in intake are biolog-
ically relevant. Serum levels of several vitamins and ele-
ments are maintained in a homeostasis to a certain degree,
even if there is a shortage in the body or an excess. For
example; magnesium is mobilised from bone if necessary
to maintain a steady serum level. This implicates that,
although serum levels are within normal range, the
metabolism at tissue level may be altered and lead to bio-
logical relevant effects.
In general, supplementation of nutrients may especially
be needed in the presence of disease, where an altered
metabolic state may enhance the need for certain nutri-
ents, vitamins or trace elements. Compared to the daily
recommended allowance, the intake of folic acid, magne-
sium, zinc, copper and selenium were lower in our MS
patients (Additional file 1.) and total energy intake (kcal)
as well. Also total energy intake of the MS patients was
lower than the energy intake of the Dutch population.
This may reflect the higher risk for malnutrition in MS
patients, because of handicap, obesity or medications [2],
and may suggests a need for dietary counseling.
There are limitations to our study that can serve as a base
for future studies.
The results point towards magnesium, calcium and iron
intake as possible candidates to be implicated in MS dis-
ease course. Ideally, a prospective dietary study in patients
with recently diagnosed MS should be undertaken to find
out if the differences in nutritional intake found can be
confirmed to be involved in disease course modulation.
In MS patients, disability may influence dietary intake,
since the more disabled may be more dependent on other
persons to cook for them. Also, after receiving the diagno-
sis MS, patients may alter their dietary habits in an
attempt to influence the disease. It is difficult for control-
ling these factors, but in this study the patients stressed
that they did not change their diet over the last years nor
were they on special diets. Furthermore, the BMI did not
differ between the groups, suggesting that there seems no
tendency for over- or underweight related to disease
course.Page 4 of 6
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nutritional survey because of the complex interaction with
nutrients and human metabolism, and potential biases
that can be difficult corrected for, the findings of this
study may suggest a role for food intake in MS. Because
the intake of several nutrients on the MS patient group
was below the daily recommended allowance, we feel that
MS patients should be made aware of possible nutritional
deficiencies. To obtain an optimal nutritional intake, our
MS patients may be advised to take dietary supplementa-
tion of magnesium, zinc, copper and selenium. A source
of magnesium is bread, grain products, vegetables and
diary products. Zinc can be found in meat, bread, cheese,
nuts and shell-fish. Copper is present in vegetables, bread,
meat, fruit and cacao products. Selenium can be found in
meat, bread and fish. For the patients with a (secondary)
progressive course of MS, additional calcium supplements
may be advised (milk, cheese, vegetables, nuts). These
findings are of importance because up to this date, no
effective neuroprotective therapy is available for MS
patients.
Conclusion
From this exploratory study we found differences in mag-
nesium, calcium and iron intake between subgroups of
MS patients that may possibly be related to MS disease
progression. This is important because no effective neuro-
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